Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Value AnalystHold
Overall Rating5/10
Generated at:2026-06-11 17:40:54
Analysis based on 5 financial reports: 2025-12-31, 2025-03-30, 2024-12-31, 2024-06-30, and 2024-03-31. Real-time stock price data as of 2026-06-11 close. TTM (Trailing Twelve Months) data used for valuation metrics. Data completeness is adequate for fundamental analysis covering financial condition, profitability, and valuation.
Overview

Pfizer, Inc. (PFE) is a leading global biopharmaceutical company with a solid market position but currently faces post-pandemic normalization challenges. The company shows mixed financial health with adequate liquidity but moderate leverage, stable but declining profitability, and appears fairly valued at current price levels. The overall fundamental picture suggests a balanced risk/reward profile with no strong catalysts for immediate outperformance.

Valuation
5/10
Profitability
4/10
Financial health
6/10
Operation Advice
  • Current shareholders should maintain their positions (Hold).
  • Potential new investors should wait for a more attractive entry point below $26.00 or clearer signs of fundamental acceleration from the non-COVID portfolio.
  • Monitor the stock within the $24.00-$29.00 trading range, with a fundamental target price of $26.00-$28.00 for the next 6-12 months based on stable earnings and P/E multiples of 18-20x.

Valuation

P/E TTM
19.48
P/E LYR
18.50
P/B MRQ
1.62
P/S TTM
--
AI Analysis
  • Pfizer appears fairly valued at the current price of $26.17, with P/E ratios slightly above historical norms but justified by the company's market position. The valuation metrics suggest no strong signal of significant undervaluation or overvaluation.
  • Current price is $26.17 as of 2026-06-11 close
  • Dynamic P/E is 18.50 and P/E (TTM) is 19.48, slightly above long-term historical average for large-cap pharmaceuticals (15-18x)
  • Price-to-Book (P/B) ratio is 1.62, a reasonable valuation trading at moderate premium to book value
  • Price-to-Sales (P/S) ratio is 2.38, within reasonable range given current ~12.5% net margin
  • Current price appears fairly valued based on provided metrics
  • Simple earnings-based valuation using P/E (TTM) of 19.48 and Diluted EPS of $1.36 yields $26.49, aligning closely with current price
  • Current price is in lower half of recent 60-day trading range ($25.24 - $28.64)
  • Reasonable near-term trading range would be $24.00 - $29.00 based on recent support/resistance levels and valuation multiples
  • Fundamental-based target price for next 6-12 months is $26.00 - $28.00 assuming stable earnings and P/E multiple of 18-20x
Valuation trend

Profitability

ROE TTM
8.90%
Net margin
12.48%
Gross margin
74.33%
Total revenue
62.58B
AI Analysis
  • Pfizer's profitability is stable but declining as the company navigates post-pandemic normalization, with high gross margins being a strength but modest returns on capital indicating challenges in translating margins to superior earnings.
  • For full year 2025, revenue declined -1.65% year-over-year to $62.58B
  • Net income attributable to shareholders declined -3.24% to $7.77B in 2025
  • Q1 2025 results show revenue decline of -7.82% YoY and net income decline of -4.75% YoY
  • Company maintains very high gross margin of 74.33% (2025 annual), characteristic of pharmaceutical industry
  • Net margin of 12.48% reflects impact of significant R&D, SG&A, and interest expenses
  • Return on Equity (ROE) is 8.90%, generally considered average (below 10%)
  • Return on Assets (ROA) is 3.69%, indicating large asset base generates relatively low level of earnings
  • Profitability is stable but declining with company navigating post-pandemic normalization phase
  • High gross margins are a strength, but translating that into superior returns on capital remains a challenge
Profitability
2024Q42025Q12025Q22025Q32025Q4
ROE TTM9.06%3.32%----8.90%
Earnings
2024Q42025Q12025Q22025Q32025Q4
Total revenue63.63B13.71B----62.58B

Financial health

Debt/Asset
58.31%
Current ratio
1.16
Quick ratio
0.87
Cash ratio
0.87
AI Analysis
  • Pfizer shows mixed financial health with adequate short-term liquidity but moderate leverage, operating as a solvent company with significant debt levels common for pharmaceutical companies funding R&D and acquisitions.
  • Current ratio of 1.16 indicates adequate but not robust short-term liquidity
  • Quick ratio of 0.87 suggests reliance on inventory to meet immediate obligations
  • Debt-to-asset ratio of 58.31% signifies moderate level of financial leverage
  • Leverage level is common for large pharmaceutical companies funding R&D and acquisitions
  • Company is solvent but operates with significant leverage
  • Liquidity metrics suggest company can meet short-term liabilities, but margin is not wide
  • Financial condition requires careful monitoring of interest coverage and cash flow
Leverage
2024Q42025Q12025Q22025Q32025Q4
Debt/Asset58.53%56.43%----58.31%
Liquidity
2024Q42025Q12025Q22025Q32025Q4
Current ratio1.171.26----1.16